Thrilled to share a significant milestone: Our pioneering research paper on targeting oxidized macrophage migration inhibitory factor (oxMIF) to treat chronic inflammatory diseases, “The Newly Engineered Monoclonal Antibody ON104, Targeting Oxidized Macrophage Migration Inhibitory Factor (oxMIF), Ameliorates Clinical and Histopathological Signs of Collagen-Induced Arthritis,” is now published in the European Journal of Pharmacology, marking the start of an impactful series this year.

This work dives into oxMIF’s implications in rheumatoid arthritis (RA) and introduces the therapeutic efficacy of ON104, an oxMIF-neutralizing antibody, validated through a murine RA model. Learn more here: https://www.sciencedirect.com/science/article/pii/S0014299923005095

Congratulations to first author Maroua Ferhat and our collaborators Prof. Ferdinando Nicoletti and Katia Mangano from the University of Catania for their remarkable contributions. This study strongly underlines oxMIF’s importance as a therapeutic target in RA and autoimmune diseases. We’re proud of our team’s dedication and eagerly anticipate further research to develop efficient oxMIF-targeting treatments for chronic inflammatory diseases.

A special thanks to our employees, supporters, and collaborators for their invaluable contributions to this remarkable achievement.